Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 2,446,867 |
|
|||||
| News | (2) | ||||||
| Day High | 598.30 | Low High |
|||||
| Day Low | 584.77 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Eli Lilly and Co | LLY | NYSE | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 11.03 | 1.87% | 599.30 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 589.43 | 584.77 | 598.30 | 598.05 | 588.27 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 71,672 | 2,446,867 | US$ 591.54 | US$ 1,447,424,452 | - | 302.14 - 629.97 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:59:46 | 15 | US$ 598.60 | USD |
Eli Lilly (LLY) Options Flow Summary
Eli Lilly and Co Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 567.73B | 949.31M | - | 28.54B | 6.24B | 6.58 | 90.91 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Eli Lilly News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LLY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 591.70 | 601.97 | 574.33 | 586.66 | 2,510,264 | 7.60 | 1.28% |
| 1 Month | 595.53 | 618.75 | 574.33 | 594.64 | 2,935,110 | 3.77 | 0.63% |
| 3 Months | 592.43 | 629.97 | 516.57 | 582.36 | 3,218,890 | 6.87 | 1.16% |
| 6 Months | 436.01 | 629.97 | 432.34 | 540.89 | 3,008,643 | 163.29 | 37.45% |
| 1 Year | 373.26 | 629.97 | 302.14 | 452.35 | 3,043,184 | 226.04 | 60.56% |
| 3 Years | 147.28 | 629.97 | 146.91 | 317.86 | 3,119,443 | 452.02 | 306.91% |
| 5 Years | 113.60 | 629.97 | 101.36 | 216.09 | 4,062,112 | 485.70 | 427.55% |
Eli Lilly Description
| Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. |
